Advertisement
Singapore markets open in 6 hours 47 minutes
  • Straits Times Index

    3,322.62
    +14.72 (+0.45%)
     
  • S&P 500

    5,273.14
    -33.87 (-0.64%)
     
  • Dow

    39,105.63
    -565.41 (-1.43%)
     
  • Nasdaq

    16,751.97
    -49.57 (-0.30%)
     
  • Bitcoin USD

    67,232.18
    -2,413.41 (-3.47%)
     
  • CMC Crypto 200

    1,466.04
    -36.63 (-2.44%)
     
  • FTSE 100

    8,339.23
    -31.10 (-0.37%)
     
  • Gold

    2,334.50
    -58.40 (-2.44%)
     
  • Crude Oil

    76.56
    -1.01 (-1.30%)
     
  • 10-Yr Bond

    4.4770
    +0.0430 (+0.97%)
     
  • Nikkei

    39,103.22
    +486.12 (+1.26%)
     
  • Hang Seng

    18,868.71
    -326.89 (-1.70%)
     
  • FTSE Bursa Malaysia

    1,629.18
    +7.09 (+0.44%)
     
  • Jakarta Composite Index

    7,222.38
    +36.34 (+0.51%)
     
  • PSE Index

    6,659.99
    +52.77 (+0.80%)
     

Weight-loss drug competition heats up. Is Wegovy in trouble?

The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million.

Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months.

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Melanie Riehl